{"id":56093,"date":"2026-04-26T22:00:28","date_gmt":"2026-04-26T22:00:28","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/56093\/"},"modified":"2026-04-26T22:00:28","modified_gmt":"2026-04-26T22:00:28","slug":"novartis-reports-high-operating-margins-following-innovative-drugs-pivot","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/56093\/","title":{"rendered":"Novartis Reports High Operating Margins Following Innovative Drugs Pivot"},"content":{"rendered":"<p><a href=\"https:\/\/www.harianbasis.co\/en\/tag\/novartis-ag\" title=\"Novartis AG\" rel=\"nofollow noopener\" target=\"_blank\">Novartis AG<\/a> reported a significant transformation into a high-margin innovative medicines company in early 2026 following the successful spin-off of its Sandoz generics division. The Swiss pharmaceutical giant recorded a core operating margin of 40.1% as its specialized drug portfolio outpaced industry peers.<\/p>\n<p>The company&#8217;s financial performance was bolstered by explosive growth in its primary treatment sectors, as reported by Detik Finance. Key growth drivers included Kisqali for breast cancer, which saw a 57% surge in sales, and the multiple sclerosis treatment Kesimpta.<\/p>\n<p>Novartis has also established a dominant position in the radioligand therapy niche. Pluvicto, a flagship cancer treatment, recorded a 42% revenue increase in constant currencies. This expansion is supported by the scaling of the FDA-approved Millburn facility in early 2026.<\/p>\n<p>            &#13;<\/p>\n<p>                            <img src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/04\/TOPC9fivC9.jpeg\" alt=\"Molina Healthcare Reports $10.2 Billion Revenue in Q1 2026\" width=\"75\" height=\"75\" loading=\"lazy\" decoding=\"async\" fetchpriority=\"low\"\/><\/p>\n<p>                &#13;<\/p>\n<p>Cash flow management remains a strength for the firm, which generated $17.6 billion in free cash flow over the last year. These funds supported strategic expansion efforts, including a $2 billion bolt-on acquisition of Excellergy in March 2026.<\/p>\n<p>Shareholder returns were addressed in early 2026 with a proposed dividend of CHF 3.70 per share. This represents a 5.7% increase and provides a yield of approximately 3%, maintaining the company&#8217;s long-term record of uninterrupted payouts.<\/p>\n","protected":false},"excerpt":{"rendered":"Novartis AG reported a significant transformation into a high-margin innovative medicines company in early 2026 following the successful&hellip;\n","protected":false},"author":2,"featured_media":56094,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[127],"tags":[14243,206,31379,4587,8514],"class_list":{"0":"post-56093","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novartis","8":"tag-kisqali","9":"tag-novartis","10":"tag-pharmaceutical-earnings","11":"tag-pharmaceutical-industry","12":"tag-radioligand-therapy"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116473261145362451","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/56093","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=56093"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/56093\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/56094"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=56093"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=56093"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=56093"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}